September 2014

New Product - Feiba-NF

Feiba-NF (factor VIII inhibitor bypassing fraction) contains factor II, IX, X (nonactivated), factor VII (activated) and 1-6 U/mL of factor VIII coagulation antigen. Feiba-NF is prepared from pooled human plasma. Feiba-NF is indicated for routine prophylaxis, control of spontaneous bleeding episodes and use in surgery in haemophilia A or B patients with inhibitors. The use of Feiba-NF is contraindicated in patients who are known to have a normal coagulation mechanism. It should not be given to patients with significant signs of disseminated intravascular coagulation (DIC) or fibrinolysis. In patients with tentative or definite diagnosis of coronary heart disease as well as in patients with acute thrombosis and/or embolism the use of Feiba-NF is only indicated in life threatening bleeding events. Feiba-NF is contraindicated in cardiac surgery involving cardiopulmonary bypass and procedures involving extracorporeal membrane oxygenation (ECMO) due to the high risk of thrombotic adverse events. Feiba-NF is available as a powder for injection with solvent in single dose glass vials in 500, 1000 and 2500 units.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au